Definition and Overview
Cellular adaptation describes the spectrum of reversible, structural and functional changes that cells and tissues undergo in response to altered physiological demands or sublethal injurious stimuli. Recognising adaptive changes on histological sections is a core diagnostic skill: they must be distinguished from reactive, dysplastic, and neoplastic processes, and their presence often signals the underlying pathological context.
The four principal adaptive responses are:
- Hypertrophy: increase in cell size without increase in cell number
- Hyperplasia: increase in cell number via proliferation
- Atrophy: decrease in cell size and/or number
- Metaplasia: replacement of one differentiated cell type by another
These responses are not mutually exclusive; hypertrophy and hyperplasia frequently coexist, and metaplasia often develops on a background of atrophy or chronic injury.
Hypertrophy
Definition and Mechanism
Hypertrophy is an increase in cell volume driven by augmented synthesis of structural proteins and organelles rather than cell division. It occurs predominantly in terminally differentiated, post-mitotic cells (cardiomyocytes, skeletal muscle fibres, neurons) that cannot respond to increased demand by dividing.
The stimulus is typically mechanical stretch or trophic signalling. In the heart, pressure overload (systemic hypertension, aortic stenosis) activates stretch-sensitive receptors and downstream pathways including IGF-1/PI3K/AKT and MAPK cascades, upregulating sarcomeric protein genes. Hormonal stimuli also drive hypertrophy: physiological uterine enlargement in pregnancy is mediated by oestrogen and mechanical distension.
Morphological Criteria
| Feature | Physiological Hypertrophy | Pathological Hypertrophy |
|---|---|---|
| Cell size | Increased, uniform | Increased, may be irregular |
| Nuclear size | Proportionally enlarged ("boxcar" nuclei in cardiomyocytes) | Enlarged, may show hyperchromasia |
| Nucleoli | Prominent | Prominent |
| Cytoplasm | Abundant, eosinophilic | Abundant; may show vacuolation or loss of myofibrils in late stages |
| Architecture | Preserved | May show disarray (e.g. hypertrophic cardiomyopathy) |
Cardiac hypertrophy is the paradigm. Concentric hypertrophy (pressure overload) shows increased wall thickness with reduced chamber volume; eccentric hypertrophy (volume overload) shows proportional wall and chamber enlargement. Histologically, cardiomyocyte diameter exceeds 15-20 µm (normal ~10-15 µm), nuclei are enlarged and hyperchromatic, and interstitial fibrosis accumulates with chronicity. Prolonged hypertrophy leads to myofibrillar loss, vacuolation, and eventual myocyte death, culminating in heart failure.
Skeletal muscle hypertrophy (e.g. athletic training) shows increased fibre diameter with peripheral nuclei maintained; fibre type proportions may shift.
Differential Diagnosis at the Microscope
- Hypertrophic cardiomyopathy (HCM): myocyte disarray, interstitial fibrosis, and asymmetric septal hypertrophy; sarcomere gene mutations (MYH7, MYBPC3)
- Storage disorders (glycogen, lipid): cytoplasmic vacuolation mimicking hypertrophy; PAS and Oil Red O stains, electron microscopy
- Rhabdomyoma: large cells with "spider cell" morphology; desmin+, myogenin+
Hyperplasia
Definition and Mechanism
Hyperplasia is an increase in cell number within a tissue or organ, driven by growth factor signalling that promotes entry of cells into the cell cycle. It requires a population capable of division (epithelial cells, fibroblasts, haematopoietic cells) or activation of tissue stem cells. Hyperplasia is always a regulated, polyclonal process; loss of this regulation is a hallmark of neoplasia.
Key signalling pathways include EGF/EGFR, oestrogen receptor (ER) signalling, and WNT/beta-catenin. Physiological examples include hepatocyte regeneration after partial hepatectomy and breast acinar proliferation during lactation. Pathological examples include endometrial hyperplasia from unopposed oestrogen and prostatic hyperplasia from androgen excess.
Morphological Criteria
- Increased number of morphologically normal or near-normal cells
- Preserved tissue architecture (lobular, glandular, or stratified patterns maintained)
- Mitotic figures present but not atypical
- No significant nuclear pleomorphism or loss of polarity
Endometrial hyperplasia illustrates the spectrum from benign to premalignant:
| WHO Category | Architecture | Cytological Atypia | Malignant Risk |
|---|---|---|---|
| Endometrial hyperplasia without atypia | Crowded glands, cystic change | Absent | <5% |
| Endometrial intraepithelial neoplasia (EIN/atypical hyperplasia) | Back-to-back glands, loss of stroma | Present | ~30% concurrent/subsequent carcinoma |
Prostatic hyperplasia (BPH): nodular proliferation of both glandular and stromal elements in the transition zone; glands lined by two cell layers (luminal columnar + basal), no atypia, no perineural invasion.
Reactive epithelial hyperplasia (e.g. squamous hyperplasia of skin, foveolar hyperplasia in Ménétrier disease): increased cell layers with preserved maturation gradient.
Differential Diagnosis at the Microscope
- Hyperplasia vs. well-differentiated carcinoma: loss of basal cell layer (p63, CK5/6, HMWCK), nuclear atypia, infiltrative growth, perineural invasion
- Endometrial hyperplasia vs. endometrioid carcinoma: stromal invasion, squamous morules, desmoplastic stroma
- Reactive vs. dysplastic: Ki-67 distribution (basal in reactive, full-thickness in dysplasia), p53 pattern
Atrophy
Definition and Mechanism
Atrophy is a reduction in cell size and/or number resulting from decreased anabolic activity, increased protein catabolism, or cell loss by apoptosis. The fundamental cellular mechanism involves reduced protein synthesis combined with accelerated degradation via the ubiquitin-proteasome pathway and autophagy (lysosomal degradation of organelles).
Causes
- Disuse: skeletal muscle atrophy from immobilisation; initially reversible (decreased cell size), later irreversible (decreased cell number via apoptosis)
- Denervation: loss of trophic neural input causes rapid muscle fibre atrophy; type grouping on reinnervation is a diagnostic feature
- Reduced blood supply/ischaemia: cerebral atrophy in atherosclerotic cerebrovascular disease; renal atrophy distal to arterial stenosis
- Inadequate nutrition: generalised wasting; protein-calorie malnutrition
- Loss of endocrine stimulation: endometrial and vaginal atrophy post-menopause (oestrogen withdrawal); prostatic atrophy after androgen deprivation therapy; thyroid atrophy in hypothyroidism
- Pressure: compression by expanding mass lesion causing ischaemic atrophy of adjacent tissue; pancreatic exocrine atrophy from ductal obstruction (e.g. cystic fibrosis, ductal adenocarcinoma)
- Ageing: senile atrophy; lipofuscin accumulation ("brown atrophy" of the heart)
Morphological Criteria
| Feature | Atrophic Tissue |
|---|---|
| Cell size | Reduced |
| Cytoplasm | Scant; may contain lipofuscin granules (golden-brown, PAS+, autofluorescent) |
| Nuclei | Smaller, may be pyknotic |
| Stroma | Relatively increased; fibrosis in chronic atrophy |
| Apoptotic bodies | May be present |
| Architecture | Simplified; glandular atrophy shows reduced gland number and size |
Denervation atrophy of skeletal muscle: angular atrophic fibres scattered among normal fibres (neurogenic pattern); ATPase histochemistry shows type grouping on reinnervation. Contrast with myopathic atrophy (rounded fibres, internal nuclei, fibre splitting).
Pancreatic exocrine atrophy: loss of acinar tissue with relative preservation of islets; fibrofatty replacement; ductal dilation if obstructive.
Endometrial atrophy: thin endometrium with small, inactive glands lined by low columnar to cuboidal epithelium; scant stroma; no mitoses.
Differential Diagnosis at the Microscope
- Atrophic glands vs. adenocarcinoma: atrophic glands retain lobular architecture, two-cell layer (basal cells p63+), no nuclear atypia; carcinoma shows infiltrative single glands, nuclear enlargement, AMACR+, basal cell loss
- Senile cardiac atrophy vs. dilated cardiomyopathy: lipofuscin, reduced myocyte size, no significant fibrosis in pure atrophy
- Neurogenic vs. myopathic atrophy: angular fibres, type grouping (neurogenic) vs. rounded fibres, internal nuclei, necrosis/regeneration (myopathic)
Metaplasia
Definition and Mechanism
Metaplasia is the reversible replacement of one mature, differentiated cell type by another, typically in response to chronic irritation, inflammation, or altered hormonal milieu. The replacing cell type is usually better adapted to the new environmental conditions. Metaplasia arises through reprogramming of tissue stem cells rather than transdifferentiation of mature cells; the stem cell adopts a different differentiation pathway.
Metaplasia is not itself premalignant, but the chronic injury that drives it can, if persistent, lead to dysplasia and carcinoma in the metaplastic epithelium.
Squamous Metaplasia
Definition: replacement of non-squamous epithelium (columnar, transitional, or glandular) by stratified squamous epithelium.
Common sites and causes:
| Site | Stimulus | Significance |
|---|---|---|
| Bronchus/bronchioles | Cigarette smoke | Precursor to squamous cell carcinoma; loss of mucociliary function |
| Endocervix (transformation zone) | Acid pH, HPV | Squamocolumnar junction; site of CIN and SCC |
| Endometrium | Chronic inflammation, tamoxifen | Squamous morules in endometrioid lesions; generally benign |
| Urinary bladder | Calculi, chronic catheterisation, schistosomiasis | Keratinising squamous metaplasia: risk of squamous carcinoma |
| Salivary gland ducts | Obstruction, necrotising sialometaplasia | May mimic mucoepidermoid carcinoma |
| Thyroid follicles | Chronic thyroiditis, Hashimoto disease | Benign; distinguish from papillary thyroid carcinoma with squamous features |
| Pancreatic ducts | Ductal obstruction (cystic fibrosis, stones) | Avitaminosis A contributes; benign |
Morphological criteria for squamous metaplasia:
- Stratified squamous epithelium with orderly maturation from basal to superficial layers
- Intercellular bridges (desmosomes) visible on H&E
- No significant nuclear atypia or loss of polarity
- Keratinisation may or may not be present depending on site
- Underlying basement membrane intact
Distinction from squamous dysplasia/carcinoma in situ:
- Dysplasia: nuclear enlargement, hyperchromasia, increased N:C ratio, loss of polarity, atypical mitoses, full-thickness atypia in high-grade
- p16 block positivity (HPV-driven), Ki-67 full-thickness in high-grade CIN
- Invasive SCC: breach of basement membrane, desmoplastic stroma
Glandular (Columnar) Metaplasia
Definition: replacement of squamous or transitional epithelium by glandular/columnar epithelium, or replacement of one glandular type by another (intestinal metaplasia).
Barrett oesophagus is the prototypic example: chronic gastro-oesophageal reflux damages squamous epithelium, which is replaced by specialised intestinal-type columnar epithelium with goblet cells. Diagnostic criteria require endoscopic columnar-lined oesophagus with histological confirmation of goblet cells (Alcian blue pH 2.5 positive). Barrett oesophagus carries a 30-40-fold increased risk of oesophageal adenocarcinoma; surveillance biopsies follow the Seattle protocol.
Intestinal metaplasia of the stomach: replacement of gastric mucosa by intestinal-type epithelium with goblet cells and absorptive cells; complication of chronic Helicobacter pylori gastritis; component of the Correa cascade (normal mucosa → chronic gastritis → atrophy → intestinal metaplasia → dysplasia → adenocarcinoma). Complete (type I) vs. incomplete (type II/III) intestinal metaplasia; incomplete type carries higher risk.
Cystitis glandularis: glandular metaplasia of urothelium, typically in the bladder; columnar cells with mucin-secreting goblet cells; associated with chronic inflammation; cystitis glandularis with intestinal metaplasia (florid type) carries low but recognised risk of adenocarcinoma.
Morphological criteria for glandular metaplasia:
- Columnar epithelium with or without goblet cells
- Mucin production (Alcian blue, mucicarmine positive)
- Preserved glandular architecture without back-to-back crowding or stromal invasion
- No significant nuclear atypia
Distinction from adenocarcinoma:
- Metaplasia: preserved architecture, no stromal invasion, no significant atypia, low Ki-67
- Adenocarcinoma: infiltrative glands, desmoplastic stroma, nuclear pleomorphism, loss of surface maturation
Immunohistochemistry in Adaptive Lesions
| Marker | Application | Pattern |
|---|---|---|
| p63 / CK5/6 / HMWCK | Basal cell layer in squamous metaplasia and hyperplasia; loss in carcinoma | Nuclear (p63); cytoplasmic (CK5/6, HMWCK) |
| p16 | Block positivity in HPV-driven dysplasia; patchy in reactive squamous metaplasia | Nuclear + cytoplasmic |
| Ki-67 | Basal/parabasal in reactive; full-thickness in high-grade dysplasia | Nuclear |
| AMACR (P504S) | Positive in prostatic adenocarcinoma; negative in atrophic glands and adenosis | Cytoplasmic granular |
| Alcian blue pH 2.5 | Goblet cell mucin in Barrett oesophagus and intestinal metaplasia | Cytoplasmic |
| CDX2 | Intestinal differentiation in Barrett and gastric intestinal metaplasia | Nuclear |
| Desmin / myogenin | Confirm myogenic lineage in hypertrophic/atrophic muscle | Cytoplasmic (desmin); nuclear (myogenin) |
Exam-Focused Diagnostic Pitfalls
- Atrophic prostate glands can mimic adenocarcinoma: retain basal cells (p63+, HMWCK+), AMACR negative, lobular architecture preserved
- Squamous metaplasia in salivary gland (necrotising sialometaplasia): lobular architecture preserved, no true invasion; can be misdiagnosed as mucoepidermoid carcinoma or SCC
- Squamous morules in endometrial lesions: bland, wirling squamous nests; not evidence of malignancy per se; assess surrounding glandular component for atypia
- Cardiac hypertrophy vs. HCM: HCM requires myocyte disarray (>20% of sampled myocardium), not just increased myocyte diameter; molecular testing for sarcomere mutations
- Denervation atrophy vs. inflammatory myopathy: angular fibres and type grouping favour neurogenic; necrosis, regeneration, and endomysial inflammation favour myopathy; MHC-I upregulation in inflammatory myopathy
- Barrett oesophagus: goblet cells required for diagnosis in most guidelines; cardiac-type mucosa without goblet cells is insufficient; p53 IHC (aberrant: strong block or complete loss) supports dysplasia
Reporting Considerations
When reporting adaptive changes, the synoptic comment should:
- Identify the adaptive change and its morphological basis
- State the likely aetiological context (e.g. "squamous metaplasia consistent with chronic irritation/smoking history")
- Exclude dysplasia and malignancy explicitly, with IHC results if performed
- Recommend clinical correlation or follow-up where the adaptive change carries malignant risk (e.g. Barrett oesophagus surveillance, keratinising squamous metaplasia of bladder)
- For metaplasia in a biopsy context, note whether the sample is adequate to exclude dysplasia
Adaptive changes are reversible if the stimulus is removed; this distinguishes them conceptually from irreversible injury and from neoplasia, and should inform the clinical management recommendation in the report.